FDA recalls Vitruvias thyroid tablets after testing finds potential ‘superpotency’; here’s who faces greater risk

Vitruvias Therapeutics has announced a voluntary recall of its thyroid tablets after tests indicated the potential for superpotency, which could lead to serious health risks. The recall specifically involves Lot Number 504950, which has been distributed throughout the United States. Patients are advised to speak with their healthcare providers before stopping their medication. The FDA also encourages consumers to report any side effects they may encounter.

Raccontata daeconomictimes.indiatimes.commedpagetoday.comqz.com